Ovarian Cancer | Specialty

ESMO 2019: Dr. Ramalingam Discusses Confirmatory Data in Advanced NSCLC

September 29th 2019

OncLive News Network On Location: ESMO 2019 Day 3

September 29th 2019

OncLive News Network On Location: ESMO 2019 Day 2

September 29th 2019

OncLive News Network On Location: ESMO 2019 Day 1

September 29th 2019

Frontline Olaparib/Bevacizumab Maintenance Combo Extends PFS in Ovarian Cancer

September 28th 2019

Frontline maintenance therapy with the combination of olaparib and bevacizumab improved median progression-free survival versus bevacizumab and placebo for patients with newly diagnosed, advanced ovarian cancer.

Niraparib Improves PFS as Frontline Maintenance in Ovarian Cancer

September 28th 2019

Frontline maintenance therapy with the PARP inhibitor niraparib improved median progression-free survival by 5.6 months compared with placebo for patients with newly diagnosed, advanced ovarian cancer who responded to platinum-based chemotherapy.

Frontline Veliparib Shows Intriguing PFS Findings in VELIA Trial

September 28th 2019

The frontline combination of veliparib, carboplatin, and paclitaxel followed by maintenance veliparib monotherapy led to a 32% reduction in the risk of progression or death compared with placebo plus chemotherapy with placebo maintenance for patients with high-grade serous ovarian cancer.

Cediranib/Olaparib Combo Shows Promise in Platinum-Resistant Ovarian Cancer

September 28th 2019

The combination of cediranib and olaparib improved progression-free survival in patients with platinum-resistant ovarian cancer, although the difference from chemotherapy did not achieve statistical significance.

Perusing Progress Made in Ovarian Cancer Treatment Paradigm in Pasadena

September 25th 2019

We traveled to Pasadena, California, for a State of the Science Summit™ on Ovarian Cancer, which featured insights from City of Hope faculty.

Dr. Gunderson on the GOG-252 Trial in Advanced Ovarian Cancer

September 19th 2019

Camille C. Gunderson, MD, discusses the phase III open-label GOG-252 trial in advanced ovarian cancer.

Dr. Moore on Research Evaluating Repeat Exposure to PARP Inhibition in Ovarian Cancer

September 19th 2019

Kathleen Moore, MD, director, Oklahoma TSET Phase I Program, and associate professor, Section of Gynecologic Oncology, Stephenson Cancer Center, discusses research evaluating repeat exposure to PARP inhibition in patients with platinum-sensitive ovarian cancer.

Growing Body of Evidence Supports Use of HIPEC in Ovarian Cancer

September 18th 2019

A large pool of evidence exists to support the use of HIPEC in ovarian cancer, and hyperthermic and other novel intraperitoneal chemotherapies should continue to be incorporated into novel clinical trial designs.

Dr. Mirza on Efficacy of Niraparib/Bevacizumab Combo in Recurrent Ovarian Cancer

September 4th 2019

Mansoor Raza Mirza, MD, chief oncologist, Department of Oncology in Rigshospitalet, Copenhagen University Hospital, discusses results from the phase II NSGO-AVANOVA2/ENGOT-OV24 trial comparing niraparib with niraparib plus bevacizumab in patients with recurrent platinum-sensitive ovarian cancer.

The New Ovarian Cancer Landscape: Many Questions, Much Hope

September 3rd 2019

In the past 5 years, the FDA has awarded 4 drugs 9 new indications for the treatment of advanced ovarian cancers. Although these approvals represent a welcome expansion of the therapeutic toolkit for this challenging malignancy, the arrival of new options has outpaced efforts to discover the best use for each medication.

Projecting the Impact of Immunotherapy in Advanced Ovarian Cancer

August 30th 2019

Rebecca C. Arend, MD, discusses several ongoing trials exploring the use of immunotherapy in patients with advanced ovarian cancer.

Navigating Among Maintenance Options in Advanced Ovarian Cancer

August 30th 2019

Camille C. Gunderson, MD, discusses the various maintenance options available in advanced ovarian cancer, as well as what factors should be considered for selecting each approach.

PARP Inhibition: A Necessity of Treatment in Recurrent Ovarian Cancer

August 29th 2019

Debra Richardson, MD, FACOG, FACS, discusses the current indications for PARP inhibitors in the recurrent setting and ongoing work being done to broaden their utility in the field.

Neoadjuvant Chemo Safer Alternative for Certain Patients With Ovarian Cancer

August 29th 2019

Linda R. Duska, MD, discusses the ongoing debate between upfront surgery and neoadjuvant chemotherapy in ovarian cancer and the data that support both options.

Strategies Emerging for PARP Inhibitor Resistance in Ovarian Cancer

August 28th 2019

Kathleen Moore, MD, combs through the various investigational strategies exploring management of resistance to PARP inhibitors in ovarian cancer.

Hope Is Not Lost on Hunt for Effective Ovarian Cancer Screening Test

August 28th 2019

Laura L. Holman, MD, discusses ongoing efforts in ovarian cancer screening and what may lie ahead for generations to come.